Overall, I thought this paper was an
interesting and well-researched look at microglia through a different lens: that
of a behavioral kind. While stress and depression have often been studied in a
more holistic and circuit-level way, I think this paper provided insight into
how small physical changes to the cells in our brain (ie. decrease in number
and size of microglia) can result in behavioral modifications and induce
depressive-like symptoms. I thought that the paper was well-written, with lots
of background research to reinforce the results that the authors found, and
reasonable explanations and conclusions drawn from their findings.
One thing that I noted while reading this paper
was in the administration of the drugs imipramine and minocycline – in the
materials and methods section, the authors note that these drugs were delivered
via water, and that the doses calculated were only averages, as animals were
housed together and doses were not administered individually. I don’t know
whether or not that is common practice for drug administration in rodents, but
I was slightly worried about the use of an ‘average’ dose for each rodent. If
one were to consume significantly more than another, would this have an effect
on the results? Later in the paper, the authors also discuss the lack of a statistically
significant effect these drugs had on behavior despite the presence of a
statistically significant effect on microglia status. They attribute this to
timing, as they state that behavioral paradigms were completed hours before the
animals were killed, allowing more time for the drugs to act on the brain
tissue following behavioral testing. If the authors believe that a few hours
would make a difference in their behavioral results, is variance in dosing not
a concern? While both are smaller details, I just question why the authors
would think that one would have an effect on their results while the other
would not.
One thing that I particularly appreciated in this
study was the use of the genetically modified rodent model, the IL-1raTG
animals. Assuming I understood exactly what the model was used for (although I’m
still not sure I completely do), I thought that this was an interesting
addition, as opposed to using and exogenous antagonist to block the IL-1 signalling pathway. The use of an over-expressed endogenous antagonist seems to me more variable,
but also has the potential to be compared to humans who may have variable
amounts of sensitivity in this pathway due to their genetic backgrounds. Although
these animals over-express the antagonist to a point of fault in the pathway, it is possible
that some people naturally have more antagonist in their system and could then
be more resistant to the deficits incurred while undergoing chronic stress. While
I would like to read and understand more about this particular rodent model and
its uses in different studies, I just thought that this was an interesting
addition to an otherwise more drug-heavy study.
Agreed about the dosing issue--not ideal, but it was the least invasive
ReplyDelete